Exelixis EXEL Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.
The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exelixis's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exelixis's change in accrued liabilities?
- Exelixis (EXEL) reported change in accrued liabilities of $4.04M in Q1 2026.
- How has Exelixis's change in accrued liabilities changed year-over-year?
- Exelixis's change in accrued liabilities decreased by 12.2% year-over-year, from $4.61M to $4.04M.
- What does change in accrued liabilities mean?
- The change in unpaid expenses that the company owes to others.
- How do you interpret change in accrued liabilities?
- An increase acts as a source of cash, suggesting the company is delaying payments or accruing expenses, while a decrease indicates a cash outflow to settle these obligations.
- How does change in accrued liabilities compare across companies?
- Standard working capital line item; peers in the pharmaceutical industry often see fluctuations based on collaboration milestones and research accruals.